Ziopharm (NASDAQ:ZIOP) has been badly leaking oil since mid-year, with yesterday’s sharp decline looking particularly ugly given the melt-up in the broader market.
“We want to assure the market that our business fundamentals are unchanged,” says CEO Laurence Cooper. The management team takes note of the restructured relationship with Intrexon, the clean-up of the balance sheet, and partnerships with Regeneron and Eden BioCell.
Source: Press Release
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.